There is one similar finding of TP53 mutations in the cell-free circulating DNA in 11% out of 205 non-cancerous control subjects, and in 35.7% early-stage and 54.1% late-stage small cell lung carcinoma (SCLC) patients [10]. This evidence concerns the gene TP53 and small cell lung carcinoma.